Liraglutide significantly reduced AGEs in ApoE−/− mice and inhibits bone resorption.[39] Through the analysis of 17 studies, liraglutide could partially improve changes in imaging and bone pathology, increase serum osteocalcin (OC) and N-terminal propeptide of type I procollagen, and reduce the C-terminal cross-linked terminal peptide of serum type I collagen, regardless of the presence of diabetes. This evidence concerns the gene BGLAP and diabetes mellitus.